Sartorius | SRT3 - Selling And Administration Expenses

Stock Price
228.15
Daily Change
-10.85 -4.54%
Monthly
-12.25%
Yearly
-5.02%
Q1 Forecast
230.71

Sartorius reported EUR218.7M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
Avita Medical AUD 20.98M 253K Jun/2025
Dianthus Therapeutics USD 8.2M 669K Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
IQVIA Holdings USD 468M 46M Dec/2025
Moderna USD 308M 40M Dec/2025
Organon & Co USD 399M 54M Sep/2025
Revvity USD 251.73M 9.82M Dec/2025
Sartorius EUR 218.7M 6.5M Sep/2025
Tectonic Therapeutic USD 4.96M 190K Sep/2025
Viatris USD 886.6M 42.1M Sep/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025